Compare Paychex, Inc. (PAYX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Paychex, Inc. trades at $111.32 (market cap $39.82B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: Paychex, Inc. pays a 4.25% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Paychex, Inc. nearer its low. Which is the better fit depends on your goals.
| PAYX | XBI | |
|---|---|---|
Market Cap | $39.82B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $147.99 | $164.28 |
52-Week Low | $85.57 | $85.16 |
Enterprise Value | $43.31B | — |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $111.96, down 2.12% on the day, with technical indicators showing a bullish trend despite overbought RSI readings. The company maintains strong profitability with 27.03% net margins and has beaten earnings estimates for three consecutive quarters. Recent dividend declarations of $1.19 per share and positive small business job growth data support the investment case.
The outlook remains positive with steady revenue growth and AI expansion driving future earnings. Key risks include macroeconomic headwinds affecting small business hiring and elevated valuation multiples. Analyst consensus is mixed with a $110 price target slightly below current levels, suggesting cautious optimism amid strong fundamentals.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
